Imbria_Logo_Colour.png
Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
08 avr. 2024 11h15 HE | Imbria Pharmaceuticals Inc.
– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
25 mars 2024 08h00 HE | Imbria Pharmaceuticals Inc.
– Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete;Phase 3 to be initiated in the 2H 2024 – BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Imbria...
Imbria_Logo_Colour.png
Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
07 nov. 2023 08h00 HE | Imbria Pharmaceuticals Inc.
– The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
16 août 2023 08h00 HE | Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
05 juin 2023 08h00 HE | Imbria Pharmaceuticals Inc.
– Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypertrophic cardiomyopathy – – IMPROVE-HCM topline data expected in 4Q 2023 – – Topline Phase 2 data...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
17 mai 2023 08h00 HE | Imbria Pharmaceuticals Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
09 janv. 2023 08h00 HE | Imbria Pharmaceuticals Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase
10 oct. 2022 08h00 HE | Imbria Pharmaceuticals Inc.
BOSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...